[
  {
    "ts": null,
    "headline": "Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet expectations for use as a standalone therapy. Hardman Johnston Global Equity Strategy has exited its position in the company following these developments. The company has decided not to pursue VX-993 as a monotherapy, which signals a shift in how its non cystic fibrosis assets are being viewed. Vertex...",
    "url": "https://finnhub.io/api/news?id=831b30dc90c25bc24736b3aa3ee66961430e4ca1ecb3bfa3fd6a67075b44acf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769926116,
      "headline": "Vertex Pain Setback Prompts Fund Exit And Recheck Of Valuation Gap",
      "id": 138322077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions for Journavx. Phase II data for pain candidate VX-993 did not meet expectations for use as a standalone therapy. Hardman Johnston Global Equity Strategy has exited its position in the company following these developments. The company has decided not to pursue VX-993 as a monotherapy, which signals a shift in how its non cystic fibrosis assets are being viewed. Vertex...",
      "url": "https://finnhub.io/api/news?id=831b30dc90c25bc24736b3aa3ee66961430e4ca1ecb3bfa3fd6a67075b44acf9"
    }
  }
]